A closed deal would be a major setback for the DOJ, which lost another merger case this year, antitrust legal experts told Healthcare Dive.
The most recent multimillion-dollar deal is the latest in a string of settlements Centene has reached over allegations it overcharged for prescription drugs and services.
Positive results from a late-stage clinical trial of the drug, called lecanemab, were a surprising success for a field used to setbacks. But doctors and researchers point out that the reported benefit appears relatively modest.
Digital pathology technologies, already popular in Europe, are primed for growth in the U.S., according to a report from KLAS research.
Even as the uninsured rate has dipped to a record low, having coverage is not enough to protect consumers from the high-cost of care, Commonwealth Fund researchers found.
Expectations are now higher for amyloid-clearing drugs after lecanemab showed it can slow the disease’s progression in a large late-stage clinical trial.
The reduction is tied to lower-than-expected spending for the controversial Alzheimer’s drug Aduhelm.
The Massachusetts Health Policy Commission required the state’s largest health system to submit a cost-cutting plan, a first for the state board.
The bill cuts funding for COVID-19 and monkeypox aid but extends two rural hospital programs.
The companies said the drug, called lecanemab, met all of its goals in the Phase 3 study. The data are a significant finding and provide stronger support for a much-debated hypothesis for treating Alzheimer’s.